Multichannel Immunosensor Platform for the Rapid Detection of SARS-CoV-2 and Influenza A(H1N1) Virus
Multichannel Immunosensor Platform for the Rapid Detection of SARS-CoV-2 and Influenza A(H1N1) Virus
复制标题
用于快速检测 SARS-CoV-2 和甲型 H1N1 流感病毒的多通道免疫传感器平台
DOI：
10.1021/acsami.1c05770
复制
发表时间：
2021-05-10
影响因子：
9.5
通讯作者：
Hao, Rongzhang
中科院分区：
文献类型：
--
作者：
Li, Jianyong;Lin, Rui;Hao, Rongzhang
2019年冠状病毒病（COVID-19）可呈现与流感感染相似的综合征，这可能使这两种重要呼吸道传染病的诊断和临床管理复杂化，尤其是在流感高峰期。针对严重急性呼吸综合征冠状病毒2型（SARSCoV-2）和流感病毒的快速和方便的床旁检测（POCT）对于迅速和有效地控制这些呼吸道流行病具有重要意义。本文基于一次性丝网印刷碳电极（SPCE）阵列，建立了用于SARS-CoV-2和甲型H1N1流感现场检测的多通道电化学免疫分析（MEIA）平台。所开发的MEIA构建有八个通道，并允许在单个阵列上进行快速检测。在SPCE表面，针对甲型H1N1流感病毒血凝素（HA）蛋白或SARS-CoV-2刺突蛋白的单克隆抗体被涂覆以捕获靶抗原，然后靶抗原与辣根过氧化物酶（HRP）标记的检测抗体相互作用以形成免疫夹心复合物。结果表明，MEIA法检测甲型H1N1流感病毒血凝素和SARS-CoV-2纤突蛋白的线性范围较ELISA法宽，灵敏度与ELISA法相当。对79份甲型H1N1临床样本的检测结果表明，拟议的MEIA平台的灵敏度与ELISA相当（阳性样本的阳性率为100%），但特异性更高，阴性样本的假阳性率为5.4%，而ELISA的假阳性率为40.5%。因此，它为感染患者的现场鉴别诊断提供了巨大的潜力，这将显著有利于有效控制和防止这些传染病在社区或资源有限的地区在未来的传播。
The coronavirus disease 2019 (COVID-19) can present a similar syndrome to an influenza infection, which may complicate diagnosis and clinical management of these two important respiratory infectious diseases, especially during the peak season of influenza. A rapid and convenient point-of-care test (POCT) for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and influenza virus is of great importance for prompt and efficient control of these respiratory epidemics. Herein, a multichannel electrochemical immunoassay (MEIA) platform was developed based on a disposable screen-printed carbon electrode (SPCE) array for the on-site detection of SARS-CoV-2 and A(H1N1). The developed MEIA was constructed with eight channels and allowed rapid detection on a single array. On the SPCE surface, monoclonal antibodies against influenza A(H1N1) hemagglutinin (HA) protein or SARS-CoV-2 spike protein were coated to capture the target antigens, which then interacted with a horseradish peroxidase (HRP)-labeled detection antibody to form an immuno-sandwich complex. The results showed that the MEIA exhibited a broader linear range than ELISA and comparable sensitivity for A(H1N1) HA and SARS-CoV-2 spike protein. The detection results on 79 clinical samples for A(H1N1) suggested that the proposed MEIA platform showed comparable results with ELISA in sensitivity (with a positive rate of 100% for positive samples) but higher specificity, with a false-positive rate of 5.4% for negative samples versus that of 40.5% with ELISA. Thus, it offers great potential for the on-the-spot differential diagnosis of infected patients, which would significantly benefit the efficient control and prevent the spread of these infectious diseases in communities or resource-limited regions in the future.